Abeona Therapeutics, Inc. is a pharmaceutical development company. Its research focuses on developing treatments for rare diseases using gene therapy and human plasma-derived therapeutics. The company is trying to find ways to address Sanfilippo Syndrome, Fanconi anemia, and Juvenile Batten disease. It has stated it anticipates starting clinical trials on an adeno-associated virus-based gene therapy for Sanfilippo syndrome in 2015.
Abeona also is developing a salt diafiltration process for purifying proteins from blood plasma and a polymer hydrogel for delivering drugs.
The company was formerly known as Access Pharmaceuticals. It was based in Dallas and was incorporated in 1989. In late 2014 the company changed its name to PlasmaTech Biopharmaceuticals. In 2015 PlasmaTech acquired a company based in Cleveland called Abeona Therapeutics which was founded in 2013. In June 2015 the parent company adopted the name Abeona Therapeutics.
The name Abeona comes from a Roman goddess who was said to protect children. The company's stock is traded on NASDAQ under the symbol ABEO.